Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on May 16, 2016, with the report date reflecting the earliest event reported on that same date. The filing addresses a corporate action approved by the Board of Directors regarding the company's capital structure and trading symbol.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
- Stock Reduction: The Board approved a 1-for-33 reverse stock split of authorized common stock (par value $0.001) and a corresponding proportional decrease in issued and outstanding shares.
- Regulatory Filing: The reduction was filed with the Nevada Secretary of State on May 18, 2016.
- Trading Symbol Change: FINRA announced the change would take effect on June 1, 2016. For 20 business days following this date, the trading symbol will be XBIOD. After this period, the symbol will revert to XBIO.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risks beyond the procedural requirement for FINRA review prior to the market effectiveness of the stock reduction. An attached press release (Exhibit 99.1) issued on June 1, 2016, provides further details on the event.
Investor Verification Checklist
- Confirm the effective date of the 1-for-33 reverse stock split in the over-the-counter markets (June 1, 2016).
- Verify the temporary trading symbol change to XBIOD and the subsequent reversion to XBIO after 20 business days.
- Review the attached press release (Exhibit 99.1) for additional context on the capital reduction.